Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Net Margin (2018 - 2025)

Dna X filings provide 8 years of Net Margin readings, the most recent being 29.31% for Q3 2025.

  • On a quarterly basis, Net Margin fell 1259.0% to 29.31% in Q3 2025 year-over-year; TTM through Sep 2025 was 5.5%, a 2164.0% increase, with the full-year FY2024 number at 60.42%, down 6039.0% from a year prior.
  • Net Margin hit 29.31% in Q3 2025 for Dna X, up from 66.8% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 117.36% in Q4 2024 to a low of 75.82% in Q1 2021.
  • Median Net Margin over the past 5 years was 29.31% (2025), compared with a mean of 21.7%.
  • Biggest five-year swings in Net Margin: plummeted -6283bps in 2023 and later soared 12694bps in 2024.
  • Dna X's Net Margin stood at 73.58% in 2021, then soared by 172bps to 53.25% in 2022, then crashed by -118bps to 9.58% in 2023, then soared by 1325bps to 117.36% in 2024, then crashed by -125bps to 29.31% in 2025.
  • The last three reported values for Net Margin were 29.31% (Q3 2025), 66.8% (Q2 2025), and 2.74% (Q1 2025) per Business Quant data.